A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma

BACKGROUND: The purpose of the current study was to evaluate the efficacy and safety of a dose increased weekly Bortezomib (Bor) based combination therapy in multiple myeloma (MM) patients. RESULTS: The overall response rate (ORR) in the modified Bor group was 76.6%, composed of 40% complete respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Daolin, Tong, Yin, Bai, Haitao, Cai, Qi, Gao, Yanrong, Wang, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342543/
https://www.ncbi.nlm.nih.gov/pubmed/27659525
http://dx.doi.org/10.18632/oncotarget.12162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342543/
https://www.ncbi.nlm.nih.gov/pubmed/27659525
http://dx.doi.org/10.18632/oncotarget.12162

Ejemplares similares